You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy
SBC: AFFIRMED PHARMA, LLC Topic: NEIAbstract Radiation induced keratopathy results in significant ocular surface disease, stem cell deficiency, vision loss, discomfort, and subsequent poor quality of life, affecting up to 23% of patients receiving radiation therapy for head and neck malignancies [1]. Studies have pointed out functional roles of corneal neurons and secretory cells of the lacrimal gland in the etiology of radiation in ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Feasibility of a mobile application for sleep and circadian rhythms in pediatric patients with acute lymphoblastic leukemia and their caregivers
SBC: ARCASCOPE INC. Topic: NHLBIABSTRACT Long-term survival rates for children diagnosed with acute lymphoblastic leukemia (ALL) currently exceed 90%. However, prolonged ALL chemotherapy, which lasts two to three years on average, is associated with significant fatigue and sleep disturbances in both children and their caregivers. In fact, patients and caregivers often identify excess fatigue and sleep disturbances as the most di ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Evaluating the efficacy of Butyric acid pro-drug nanoparticle in retinal neuroprotection
SBC: Nutriforward, LLC Topic: 100Project Summary Choroidal neovascularization (CNV) occurs in both age-related macular degeneration (AMD) and diabetic retinopathy (DR). While anti-VEGF treatment has improved the visual outcome considerably, they are far from achieving a 100% success rate (non-responsiveness between 8 and 50%). Inherited retinal degenerations (IRDs) are a group of heterogeneous, progressive, visually debilitating ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Automating Assessment of Contextualization of Care During the Clinical Encounter
SBC: Institute for Practice and Provider Performance Improvement, Inc. Topic: 600Background: Large scale studies have demonstrated that when patients struggle with life challenges that complicate their care (e.g., a lack of social support, competing responsibilities, or financial hardships), health care providers can improve health care outcomes and lower costs if they attempt to identify these “contextual factors” and address them in their care plan – a process termed ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Using in-vivo Real-time Biosensor to Evaluate Prodrugs Designed to Prolong Therapeutic Effects for Smoking Cessation.
SBC: SPACERX LLC Topic: NIDAABSTRACT Developing drugs that target the central nervous system (CNS) is hampered by an inability to perform direct in vivo preclinical measurements. Here, we propose to identify an optimal smoking cessation drug candidate by monitoring how our newly synthesized prodrugs alter real-time brain dopamine responses to nicotine. Varenicline (CHANTIX®) is the leading FDA-approved oral medication for s ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Motion-Resistant Background Subtraction Angiography with Deep Learning:Real-Time, Edge Hardware Implementation and Product Development
SBC: CLEARVOYA LLC Topic: NHLBICatheter Digital Subtraction Angiography (DSA) is an imaging technique that was developed in the 1980s to allow physicians to visualize blood vessels. Today, this technology is utilized for minimally-invasive interventions that treat numerous devastating pathologies, including stroke and myocardial infarction, diseases that disproportionally impact underserved minority patient populations.Catheter ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection
SBC: Covira Surgical Topic: NIAIDSUMMARY Covira Surgical, Inc. is developing CS-0003, a first-in-class, orally administered non-antibiotic therapy for preventing infections in patients undergoing gastrointestinal (GI) surgeries. Despite improved surgical procedures, broad use of antibiotics, mandated asepsis measures, and enhanced recovery programs, post-surgical infections remain a clear and present danger to patients. Surgical ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of drug conjugates of R-spondin peptibodies for the treatment of colorectal cancer
SBC: WNTRIX INC Topic: 102PROJECT SUMMARY Colorectal cancer is still a major cause of cancer-related death in the world and only a small subset of patients benefits from therapy by immune checkpoint inhibitors. Antibody–drug conjugates (ADCs) are monoclonal antibodies (mAbs) that are covalently linked to cell-killing drugs and have emerged as a major modality in anti-cancer treatment. This approach combines high specific ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
SMALL MOLECULE THERAPEUTIC FOR ALZHEIMER'S DISEASE
SBC: SOMATOLYNK, INC. Topic: NIAAn estimated one out of eight individuals over the age of 65 has Alzheimer’s disease (AD), with a prevalence of 1-in-3 for those over age 85. There are approximately 5.8 million people in the USA with AD, with a global projection of over 150 million by 2050. There remains a lack of effective treatment to halt disease progression. Somatostatin receptor-4 (SSTR4) represents an innovative and viabl ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing RNA therapeutics for rare neurodevelopmental disorders
SBC: Dayi Therapeutics, Inc. Topic: NICHDPROJECT SUMMARY Developing RNA therapeutics for rare neurodevelopmental disorders Monogenic diseases caused by mutations in single genes are individually rare, but collectively common affecting 10% of the world population. Many of these diseases are disabling or even life threatening with no available treatment. The underlying molecular mechanisms vary. Both loss of gene function and gain of toxic ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health